Paroxetine-maprotiline

From Psychiatrienet
Revision as of 08:04, 27 July 2009 by Walter (talk | contribs)
Jump to: navigation, search
paroxetine
Type Antidepressant
Group SSRI
links
Medscape paroxetine
PubChem 43815
PubMed paroxetine
Kompas (Dutch) paroxetine
Wikipedia paroxetine
Maprotiline
Type Antidepressant
Group NRI
links
Medscape Maprotiline
PubChem 4011
PubMed Maprotiline
Kompas (Dutch) Maprotiline
Wikipedia Maprotiline

Switch medication from paroxetine to maprotiline.[1] [2]

Nietinrijdenbord.png Stop paroxetine
  • Day 0: gradually reduce dosage of paroxetine to a maximum of 20 mg/day when this dosage is > 20 mg/day.
  • Day 1: reduce dosage of paroxetine to a maximum of 10 mg/day.
  • Day 8: stop dosage of paroxetine.
Eenrichtingbord.png Start maprotiline

Caution is necessary.

  • Day 8: start administration of maprotiline in a low dosage of 25 mg/day.
  • Day 15: increase administration of maprotiline to a dosage of 50-100 mg/day.
  • "Start low, go slow" is not required, but caution is necessary!
Infobord.png More information
  • Paroxetine slows the metabolism of maprotiline via CYP1A2 and CYP2D6.
  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.